GlassScriptPhysician profile
Paul C Grimm
NPI 1184705386
$98,511.47
in general payments reported to CMS, 2019-2025
12 companies · $4,893 in 2025
The $4,893 reported for 2025 was more than what 87% of Pediatric Nephrology providers received nationally (typical 2025 total: $131).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $12K · 2022: $29K · 2023: $4,338 · 2024: $17K · 2025: $4,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $3,122 · Honoraria: $1,992 · Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,142.50 |
| Travel and Lodging | $3,121.60 |
| Honoraria | $1,992.00 |
| Food and Beverage | $1,109.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $69,999.81 | 2019-2023 | Procysbi |
| Amgen INC. | $17,134.09 | 2024 | Procysbi, Aranesp |
| Travere Therapeutics, INC. | $4,785.29 | 2025 | Filspari |
| Recordati_rare_diseases_inc. | $3,422.11 | 2019-2023 | Cystadrops, Cystadane, Carbaglu |
| Genentech, INC. | $2,070.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $625.44 | 2019-2022 | |
| Veloxis Pharmaceuticals, INC. | $121.49 | 2019 | |
| Apellis Pharmaceuticals, INC. | $108.08 | 2025 | |
| Alnylam Pharmaceuticals INC. | $105.15 | 2023 | Oxlumo |
| Bayer Healthcare Pharmaceuticals INC. | $65.04 | 2023 | |
| Novartis Pharmaceuticals Corporation | $46.71 | 2023 | |
| Genzyme Corporation | $28.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Grimm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.